GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

PG-102

Company
ProGen. Co., Ltd.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for PG-102 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06891287

    An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers.

    Not yet reported RANI Therapeutics 60 participants Est. completion 2027-06-01 1 site Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Terminated NCT NCT00787137

    Single Dose PG102 in Patients With Active Psoriatic Arthritis

    Not yet reported PanGenetics UK Limited 17 participants Est. completion 2010-05 1 site
    Other conditions: Arthritis, Psoriatic
    View official trial listing →
  • Completed NCT NCT01106703

    The Effects of PG102, a Water Soluble Extract From Actinidia Arguta, on Serum Total IgE Levels

    Not yet reported Seoul National University Hospital 90 participants Est. completion 2008-04 2 sites
    Other conditions: Asymptomatic Subjects With Atopy and Elevated Serum IgE
    View official trial listing →
  • Completed NCT NCT06309667

    A Study to Investigate the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of PG-102 (MG12) in Healthy Adult and Obesity Participants.

    Not yet reported ProGen. Co., Ltd. 102 participants Est. completion 2025-02-05 1 site Stand-alone
    Other conditions: Healthy, Overweight
    View official trial listing →
  • Active, not recruiting NCT NCT06712615

    Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes

    Not yet reported ProGen. Co., Ltd. 144 participants Est. completion 2025-10-30 14 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07187856

    Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus

    Not yet reported ProGen. Co., Ltd. 80 participants Est. completion 2026-12 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07677891

    Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus

    Not yet reported ProGen. Co., Ltd. 60 participants Est. completion 2027-06 Stand-alone
    Type 2 diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: PG-102, PG-102(MG12)

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.